Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Apatinib Combined With Oral Vinorelbine in Pretreated Metastatic HER2 Negative Breast Cancer

Next Previous
X
Search
Trial Profile

Phase II Study of Apatinib Combined With Oral Vinorelbine in Pretreated Metastatic HER2 Negative Breast Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivoceranib (Primary) ; Vinorelbine (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 05 Jun 2018 Results (n=40) assessing the efficacy and safety of the oral vinorelbine-Apatinib combination in pre-treated metastatic breast cancer, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 13 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top